Back

First-Line Options in EGFR-Mutated Advanced NSCLC: Selecting and Initiating Subcutaneous Amivantamab Plus Lazertinib With Prophylactic Strategies

First-Line Options in EGFR-Mutated Advanced NSCLC: Selecting and Initiating Subcutaneous Amivantamab Plus Lazertinib With Prophylactic Strategies

Edgardo Santos, MD, FACP, FASCO, of Starling Oncology, and Wade Iams, MD, MSCI, of Tennessee Oncology, work through how they choose among first-line options for EGFR exon 19 deletion and L858R advanced non–small cell lung cancer. Both favor a combination regimen over third-generation tyrosine kinase inhibitor monotherapy, citing the overall survival advantage seen with amivantamab plus lazertinib in MARIPOSA and with platinum-based chemotherapy plus osimertinib in FLAURA2. Dr Santos cites 3-year intracranial progression-free survival of 36% with the combination vs 18% with osimertinib in MARIPOSA as the reason he favors it when brain metastases are present. Dr Iams describes the pragmatic COPERNICUS study, which pairs every-4-week subcutaneous amivantamab with prophylactic anticoagulation and enhanced dermatologic prophylaxis, and reports rash falling from roughly 50% to 60% down to 20% to 30%. Dr Santos details his day 1 order set, and across 2 cases the faculty weigh brain metastases, chronic kidney disease, prior thrombosis, travel distance, and patient preference.

First-Line Options in EGFR-Mutated Advanced NSCLC: Selecting and Initiating Subcutaneous Amivantamab Plus Lazertinib With Prophylactic Strategies

Episodes

All
All

Wade Iams, MD, MSCI, of Tennessee Oncology, describes how he opens the first treatment conversation with patients who have EGFR-mutated advanced non–small cell lung cancer and with their families, after Edgardo Santos, MD, FACP, FASCO, of Starling Oncology, notes that grade 3 or higher adverse events were more common with amivantamab plus lazertinib than with osimertinib in MARIPOSA.

Wade Iams, MD, MSCI, of Tennessee Oncology, explains how his team keeps patients on prophylactic strategies when starting subcutaneous amivantamab plus lazertinib for EGFR-mutated advanced non–small cell lung cancer: repeated touches from multiple members of the care team over time, including his own counseling, nursing education at the injection visit, a call from a specialty pharmacist for the oral agent, and follow-up by advanced practice providers.